Clinical Trial Update: Safety and Efficacy Study of AT-101 in Combination With Docetaxel and Prednisone in Men With HRPC [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating AT-101 in combination with docetaxel and prednisone for hormone-refractory prostate cancer has completed, with safety and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• AT-101 (gossypol acetic acid)
• DOCETAXEL (DOCETAXEL)
• PREDNISONE (Prednisone)

Snippet

Sponsor: Ascenta Therapeutics | Conditions: Prostate Cancer | Phase 1, Phase 2 | Status: COMPLETED